**Background of ARHGDIB Antibody**
ARHGDIB (Rho GDP-dissociation inhibitor beta), also known as RhoGDI2 or LyGDI, is a member of the RhoGDI family that regulates Rho GTPases by inhibiting GDP/GTP exchange and sequestering them in the cytoplasm. These GTPases, such as RhoA, Rac1. and Cdc42. are critical for cytoskeletal dynamics, cell motility, and signal transduction. ARHGDIB is particularly abundant in hematopoietic and immune cells, where it modulates immune responses, T-cell activation, and phagocytosis.
Antibodies targeting ARHGDIB are essential tools for studying its expression, localization, and interactions with Rho GTPases in physiological and pathological contexts. Research has linked ARHGDIB dysregulation to cancer progression, including roles in metastasis suppression (e.g., in bladder cancer) or promotion (e.g., in leukemia), depending on cellular context. It also influences inflammatory diseases by regulating leukocyte migration and cytokine production.
ARHGDIB antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate its tissue distribution, expression levels, and post-translational modifications. These studies help clarify its dual role in cancer and immune regulation, offering insights into therapeutic targeting. The antibody’s specificity and validation (e.g., knockout validation) are critical to ensure accurate detection, given the high homology among RhoGDI family members.